Skip to main content
. Author manuscript; available in PMC: 2015 Jun 7.
Published in final edited form as: Hematol Oncol Clin North Am. 2009 Oct;23(5):949–v. doi: 10.1016/j.hoc.2009.07.005

Figure 3.

Figure 3

Overall survival by therapy (modified hyper-CVAD with rituximab compared with hyper-CVAD alone) in the younger subsets (age less than 60 years) with de novo CD20 positive precursor B-cell ALL. No difference in survival was observed with rituximab for the elderly subset (not shown).